This is the authors' abstract. We don't add key points for this paper.
A new family of group 4 permethylpentalene (C8Me62-; Pn*) aryloxide and alkoxide complexes have been synthesised and fully characterised by multinuclear NMR spectroscopy and single-crystal X-ray diffraction; (η8-C8Me6)Zr(OR)2 (R = tBu (1), 2,6-Me-C6H3 (2), 2,6-iPr-C6H3 (3) and 4-OMe-C6H4 (4)), (η8-C8Me6)Zr (OR) (R = 2,6-tBu-C6H3 (5) and 2,6-tBu-4-Me-C6H2 (6)), (η8-C8Me6)ZrCp(OR) (R = tBu (7), 2,6-Me-C6H3 (8) and 2,6-iPr-C6H3 (9)), (η8-C8Me6)TiCp(O-2,6-Me-C6H3) (10) and (η8-C8Me6)ZrCpMe(OR) (R = 2,6-Me-C6H3 (11), 2,6-iPr-C6H3 (12) and 2,4-tBu-C6H3 (13)). 2, 3, 6, 7, 9, 10 and 12 were studied as initiators for the ring-opening polymerisation (ROP) of l-lactide, and 2, 3, 6, 7 and 10 were studied as initiators for the ROP of rac-lactide. 3 was found to be the most active initiator for the ROP of l-lactide (kobs = 0.35 h-1) and 2 for the ROP of rac-lactide (kobs = 0.21 h-1). These initiators produced isotactic PLA for the ROP of l-lactide and moderately heterotactic enriched (maximum Pr of 0.69) or atactic PLA for the ROP of rac-lactide with polymer chains consisting of polylactic acid repeat units with -OR and -OH end groups.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Turner et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: